Navigo Proteins, ITM Isotope Technologies Munich Partner on Targeted Radionuclide for Solid Tumors
The firms will combine a FAP-targeted molecule with a radioisotope to create a therapy that may treat a variety of cancers.
Source: precisiononcologynews.com